Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07056556 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 31 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07136558 | Evaluation of ICP-B794 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 410 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07135128 | A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 20 | Xiaorong SunOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06907043 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.(EIK1004-001) | recruiting | Phase 1 / Phase 2 | 130 | Eikon TherapeuticsINDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT05725291 | AMT-116 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Multitude Therapeutics Inc.INDUSTRY | 3 | Aug 17, 2025 | clinicaltrials |
| NCT05761223 | A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | recruiting | Phase 1 / Phase 2 | 151 | 1ST Biotherapeutics, Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06036121 | A Study of ADRX-0706 in Select Advanced Solid Tumors | active not recruiting | Phase 1 | 144 | Adcentrx TherapeuticsINDUSTRY | 2 | Aug 17, 2025 | clinicaltrials |
| NCT06487455 | A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors. | recruiting | Phase 1 | 170 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05906862 | AMT-253 in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 54 | Multitude Therapeutics (Australia) Pty LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07122063 | Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 266 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05717348 | A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours | active not recruiting | Phase 1 | 120 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06547957 | A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 55 | iTeos TherapeuticsINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07070349 | A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05836948 | The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 174 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06375564 | Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression | recruiting | Phase 1 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06480240 | A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 117 | OBI Pharma, IncINDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT07100249 | A Study of HDM2012 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 129 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07110883 | A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 400 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT04778839 | Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 98 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07107178 | A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 6, 2025 | clinicaltrials |
| NCT05718557 | Study of PYX-106 in Solid Tumors | active not recruiting | Phase 1 | 47 | Pyxis Oncology, IncINDUSTRY | 3 | Aug 3, 2025 | clinicaltrials |
| NCT07101549 | Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18) | not yet recruiting | Phase 1 | 25 | changjianhuaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06463340 | Study of SGR-3515 In Participants With Advanced Solid Tumors. | recruiting | Phase 1 | 52 | Schrödinger, Inc.INDUSTRY | 2 | Aug 1, 2025 | clinicaltrials |
| NCT07098052 | A Study of HDM2020 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06484556 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | Tao ZhangOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07092748 | A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 110 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06220838 | Study SC-101 in Subjects With Advanced Malignancies | recruiting | Phase 1 | 100 | Tianjin ConjuStar Biologics Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06710158 | Study of SC-102 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 120 | Tianjin ConjuStar Biologics Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07088588 | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 105 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 66 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06208410 | A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 306 | Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06428500 | QTX3046 in Patients With KRAS G12D Mutations | active not recruiting | Phase 1 | 240 | Quanta TherapeuticsINDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05217693 | A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 288 | Bliss Biopharmaceutical (Hangzhou) Co., LtdINDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT05978102 | A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 183 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03772561 | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies(MEDIPAC) | recruiting | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05701709 | Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 395 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077252 | Phase I/II Study of SCTB39G in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT01843413 | Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases | active not recruiting | Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06666270 | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06929663 | A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 48 | AkesoINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05881525 | NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 18 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06993870 | Phase I Study of HBT-708 for Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT07061639 | A Study of QLS5133 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 212 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07057349 | CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer | not yet recruiting | Phase 1 | 40 | Cytosite Biopharma Inc.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06277219 | A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)(LIGHTSPEED-1) | recruiting | Phase 1 / Phase 2 | 150 | Latticon Antibody Therapeutics, IncINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 22, 2025source: clinicaltrials